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EVIDENTIARY STANDARDS FOR DRUG APPROVALS IN THE 21ST 
CENTURY CURES ACT: A CONTINUED TREND TOWARDS 
VALUING ACCESS OVER SAFETY FOR PHARMACEUTICAL DRUGS 
Farrah R. Raja* 
The Food and Drug Administration (“FDA”), tasked with 
promoting and protecting public health, has long been recognized 
as the gatekeeper for drugs. However, the agency has not been 
immune from criticism from patients and industry stakeholders 
over its time-consuming and clinical data-driven approval 
processes, alleged to hinder potentially effective drugs from 
reaching the market as quickly as they could. In December of 
2016, the signing of the 21st Century Cures Act (“Cures Act”), a 
piece of “landmark” legislation that alters the rigorous approval 
processes for drugs by allowing data other than those derived from 
clinical trials into the approval process consideration, came as a 
triumph to these critics. These critics lauded the legislation as a 
win for both patient access and innovation. However, this 
“triumph” may come at an expense: safety. This Recent 
Development examines the key, relevant provisions of the Cures 
Act relating to the different standards of evidence required for 
drug approvals, and how the implementation of these provisions 
will impact the future of safe and effective drugs, given our current 
framework for drug approvals. 
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I: INTRODUCTION 
The recent enactment of the 21st Century Cures Act1 into law 
has ignited a sense of hope and optimism in patients and other 
industry stakeholders who are disillusioned with regulatory 
obstacles that impede the ability of drugs to enter the market in an 
expeditious manner.2 The legislation is acclaimed for its attempts 
to advance new therapies and treatments by accelerating the 
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1 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat. 1033 (2016). 
2 Elaine Schattner, Why Patients Support the 21st Century Cures Act, FORBES 
(Nov. 30, 2016, 9:54 AM), 
http://www.forbes.com/sites/elaineschattner/2016/11/30/why-patients-support-
the-21st-century-cures-act/#12a60850ac37. 
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Federal Drug Administration (“FDA”) approval3 process for new 
drugs.4 Patients like Janet Freeman-Daily, a sixty-year-old woman 
who has been living with advanced lung cancer for the past five 
years, see the bill as a victory over “paperwork” hurdles that 
prevent potentially effective drugs from reaching the market.5 For 
Freeman-Daily, the Cures Act represents an opportunity to 
accelerate drug approval for oncogene-driven cancers.6 Given the 
complexity surrounding drug discovery, including the inherent risk 
involved in scientific uncertainty, approving a new drug for 
market, by no means, is a simple process.7 It can take anywhere 
from ten to fifteen years to approve a new drug, and the estimated 
costs can run into the hundreds of millions of dollars.8 The Cures 
Act should alleviate the many concerns patients and industry 
stakeholders have about a lengthy and time-consuming approval 
process. Critics, like law professor Ana Santos Rutschman,9 
however, worry that hastening the drug approval process will not 
come without costs.10 According to Santos Rutschman, the Cures 
                                                
 3 It is important to distinguish between drug approval and the FDA’s review 
process for drugs at the onset. Drug approval encompasses all of the time that 
goes into the development of the drug, including initial research, the discovery 
of the medicine, preclinical development testing, and clinical trial testing. Drug 
review, on the other hand, refers to the FDA’s review of all of the data 
submitted with the new drug’s application for market approval. The FDA’s Drug 
Review Process: Ensuring Drugs are Safe and Effective, U.S. FOOD AND DRUG 
ADMIN., 
https://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm. (last 
visited Mar. 20, 2017). 
 4 130 Stat. 1033. 
 5 Schattner, supra note 2. 
 6 Id. 
 7 BERNARD LO & MARILYN J. FIELD, CONFLICT OF INTEREST IN MEDICAL 
RESEARCH, EDUCATION, AND PRACTICE, 23 (2009) (ebook). 
 8 Id. 
 9 Professor Santos Rutschman is the Jaharis Faculty Fellow in Health Law and 
Intellectual Property at DePaul University College of Law. Ana Santos 
Rutschman, DEPAUL UNIV. COLL. OF L., http://law.depaul.edu/faculty-and-
staff/faculty-a-z/Pages/ana-santos-rutschman.aspx (last visited Mar. 20, 2017). 
 10 Ana Santos Rutschman, Faster Drug & Medical Device Approvals Under 
21st Century Cures Act Raises Patient Safety Concerns, DRUG DISCOVERY & 
DEV. (Jan. 16, 2017, 8:54 AM), http://www.dddmag.com/article/2017/01/faster-
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Act may represent a sacrifice between safety and efficacy of drugs 
in exchange for quicker delivery to patients.11 
President Obama signed the Cures Act into law in December of 
2016 after it passed both the House and the Senate with bipartisan 
support. The bill, spanning almost 1,000 pages in length, 
champions several initiatives in addition to providing funding for 
these initiatives.12 The bill authorizes funding for countering the 
opioid epidemic,13 cancer research through the “Moonshot 
Initiative,”14 mental health parity implementation,15 and precision 
medicine efforts.16 The aforementioned initiatives have garnered 
praise from the majority of people, however, the most contentious 
parts of the Cures Act are those that address the evidentiary 
standards that can be used in the FDA’s approval process for 
drugs.17 
This Recent Development argues that while the Cures Act’s 
provisions that relax the evidentiary standards used in the FDA 
approval processes for drugs may help patients access drug 
treatments and therapies more quickly and might appear to further 
innovation by removing regulatory barriers, the hastened process 
authorized by these provisions poses a threat to both patient safety 
and innovation in developing effective treatments. This paper 
proceeds in six parts. Part II examines the FDA and how its 
regulatory drug standards have evolved since its inception, and 
increased utilization of expedited drug development and approval 
programs. Part III explores the legislative history behind the Cures 
Act. Part IV discusses the likely impact of the Cures Act’s FDA 
provisions that encourage the use of real-world evidence, surrogate 
endpoints, patient outcome data, and data summaries in drug 
                                                                                                         
drug-medical-device-approvals-under-21st-century-cures-act-raises-patient-
safety-concerns. 
 11 Id. 
 12 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat. 1033 (2016). 
 13 Id. § 1003. 
 14 Id. § 1001. 
 15 Id. § 13001–07. 
 16 Id. § 2011. 
 17 Jerry Avorn & Aaron S. Kesselheim, The 21st Century Cures Act—Will it 
Take Us Back in Time?, NEW ENG. J. MED. 2473, 2474 (2015). 
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approvals. Part V examines the broader policy implications of the 
Cures Act on patients, stakeholders, and the legitimacy of the 
FDA. Finally, Part VI will conclude. 
II: THE FDA - TRACING ITS EVOLUTION 
In an effort to place the significance of the Cures Act’s drug 
alteration provisions into context, this section introduces the reader 
to the FDA and the historical evolution of its regulations and 
control. Part A provides background information about the FDA 
and its role in the development and marketing of drugs. Part B 
supplies a more thorough discussion of the agency’s review 
processes for approving drugs than was mentioned in the 
Introduction.18 Part C gives an overview of special approval 
pathways that have been used by the FDA. Part D examines past 
instances of less than rigorous drug approvals, the negative 
repercussions that subsequently resulted, and what these past 
situations can teach us about what the Cures Act may hold for the 
future of drug safety and efficacy. 
A. The FDA: The Gatekeeper 
The FDA has long been regarded as the gatekeeper of the 
American pharmaceutical industry.19 The FDA has the power “to 
sculpt medical and scientific concepts,”20 to determine which drugs 
can enter the market, to determine how medical success is defined, 
and to “influence how citizens live and die.”21 Undoubtedly, the 
agency’s impact on patients’ lives and the entire pharmaceutical 
industry is far-reaching. 
While the FDA was originally formed in 1906 with the passage 
of the Pure Food and Drug Act of 1906—that was aimed at 
preventing the adulteration and mislabeling of food and drug 
products—the scope of the agency’s regulatory authority over the 
pharmaceutical industry was not fully realized until the passage of 
                                                
 18 See supra PART I. 
 19 DANIEL CARPENTER, REPUTATION AND POWER: ORGANIZATIONAL IMAGE 
AND PHARMACEUTICAL REGULATION AT THE FDA 1 (2010). 
 20 Id. 
 21 Id. 
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the Federal Food, Drug, and Cosmetic Act (“FDCA”)22 in 1938.23 
The FDCA was passed in the aftermath of the elixir sulfanilamide 
tragedy24 that took the lives of approximately one hundred people.25 
The drug was not tested for safety, as was the case for many new 
drugs, since prior to the enactment of the FDCA, new drugs did not 
undergo safety scrutiny.26 The FDCA gave the FDA stricter control 
over drugs.27 The FDCA also further strengthened the agency’s 
ability to enforce the new law.28 
While the enactment of the FDCA addressed safety concerns 
associated with drugs, there was still no requirement that drug 
firms prove the effectiveness of the drugs for which they sought 
approval.29 This changed with the monumental passage of the 1962 
Kefauver-Harris Drug Amendments30 to the FDCA. Under the 
1962 Amendments, drug companies now had to prove not only that 
the drug was safe for its intended use, but also provide “substantial 
evidence of effectiveness for the product’s intended use.”31 The 
most sweeping change that the 1962 Amendments brought, 
however, was the requirement that evidence supporting the drug 
come from “adequate and well-controlled studies.”32 Without a 
                                                
 22 Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-17, 52 Stat. 1040 
(1938). 
 23 CARPENTER, supra note 19, at 1. 
 24 During the elixir sulfanilamide tragedy, 105 individuals died after taking 
the drug elixir sulfanilamide, intended to treat infections. The drug was later 
found to have a toxic ingredient in its solution. Carol Ballentine, Taste of 
Raspberries: Taste of Death: The 1937 Elixir Sulfanilamide Incident, U.S. FOOD 
AND DRUG ADMINISTRATION (Jun. 1981), 
http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/Sulfanil
amideDisaster/. 
 25 Id. 
 26 Id. 
 27 See 52 Stat. 1040. 
 28 Id. 
 29 Michelle Meadows, Promoting Safe and Effective Drugs for 100 Years, 
U.S. FOOD AND DRUG ADMIN. (Jan.––Feb. 2006), 
http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/Promoti
ngSafeandEffectiveDrugsfor100Years/. 
 30 Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780 (1962). 
 31 Meadows, supra note 29; see also 76 Stat. 781. 
 32 Meadows, supra note 29 (emphasis added). 
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doubt, the Amendments thrust the importance of relying on 
thorough and controlled effectiveness studies into the forefront.33 
As Part B discusses, this reliance on clinical data from controlled 
trials is fundamental for drug approval.34 
B. FDA Review Processes for Drugs 
The process of getting a new drug approved on the market is a 
process that is rigorous and time-consuming for both the agency 
and for drug sponsors. Following its initial manufacture and before 
it can enter the market for sale, a drug must demonstrate 
“substantial effectiveness”35 and safety for its intended use.36 The 
FDA makes this determination after reviewing results from clinical 
trials submitted by the drug manufacturer at various stages in the 
process.37 
There are roughly seven stages for new drug development and 
review.38 The first stage, a very crucial one, begins when drug 
sponsors submit an Investigational New Drug Application 
(“IND”). During this stage in the process, sponsors must submit 
results from “preclinical” testing in laboratory animals, in addition 
to a proposed plan for human testing.39 If the results do not 
demonstrate “reasonable safety,”40 the FDA can reject the drug for 
testing in humans, thereby ending its review.41 Review of the IND 
                                                
 33 Jeremy A. Greene et al., Reform, Regulation, and Pharmaceuticals – The 
Kefauver-Harris Drug Amendments at 50, NEW ENG. J. MED 1481 (2012). 
 34 See infra FDA Review Processes for Drugs. 
 35 “Substantial evidence of effectiveness” is shown when qualified experts 
have reviewed data from adequate and well-controlled studies, and can conclude 
from the results of the data that the drug will have its intended effect for its 
prescription and labeling uses. Federal Food, Drug, and Cosmetic Act, Pub. L. 
No. 75-17, 52 Stat. 1040 (1938). 
 36 The FDA’s Drug Review Process: Ensuring Drugs are Safe and Effective, 
supra note 3. 
 37 Id. 
 38 Id. 
 39 Id. 
 40 Reasonable safety is demonstrated when, based on scientific evidence, the 
probable benefits from using the drug for its intended use outweigh the probable 
risks associated with using the drug. 52 Stat. 1040. 
 41 The FDA’s Drug Review Process: Ensuring Drugs are Safe and Effective, 
supra note 3. 
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is a joint collaborative process that involves both the FDA and an 
Institutional Review Board,42 a panel of scientists and non-
scientists whose main objective in studies involving human 
research subjects is to review and assess the study itself, the 
study’s consent procedures, and the study’s safety protocols.43 
Once the FDA deems the study “reasonably safe” for testing in 
humans, the sponsor may begin clinical testing, consisting of three 
phases: Phase 1, Phase 2, and Phase 3.44 During Phase 1 testing, 
studies are conducted on the drug’s impact on healthy volunteers, 
with the main objective targeted at finding out the drug’s side 
effects on humans.45 Once Phase 1 testing is completed and 
reviewed, if the results do not show “unacceptable toxicity,” the 
drug may move on to Phase 2 testing.46 While Phase 1 testing is 
concerned with a drug’s safety, Phase 2 testing is most concerned 
with the drug’s effectiveness.47 The subjects involved in Phase 2 
testing are individuals with certain illnesses or diseases.48 During 
this Phase, through controlled trials, researchers compare similar 
patients who are given a placebo or different kind of drug in place 
of the drug being tested.49 Through Phase 2 testing, the drug’s 
safety is still evaluated, in addition to the short-terms side effects 
of the drug.50 Once Phase 2 testing is complete and has 
demonstrated that the drug is effective, the FDA and drug sponsors 
must come to an agreement on how Phase 3 testing will proceed.51 
                                                
 42 “[Institutional Review Board]s approve the clinical trial protocols, which 
describe the type of people who may participate in the clinical trial, the schedule 
of tests and procedures, the medications and dosages to be studied, the length of 
the study, the study’s objectives, and other details. IRBs make sure the study is 
acceptable, that participants have given consent and are fully informed of their 
risks, and that researchers take appropriate steps to protect patients from harm.” 
Id. 
 43 Id. 
 44 Id. 
 45 Id. 
 46 Id. 
 47 The FDA’s Drug Review Process: Ensuring Drugs are Safe and Effective, 
supra note 3. 
 48 Id. 
 49 Id. 
 50 Id. 
 51 Id. 
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Phase 3 studies are targeted at gathering additional information 
about the drug’s safety and effectiveness by (1) studying the drugs 
effects on different populations, (2) using different dosages, and 
(3) studying the drug’s effects when used in combination with 
other drugs.52 Phase 3 testing concludes with a review meeting 
between the drug sponsor and the FDA. 
After the three phases of testing are complete, the sponsor 
seeks the approval of the FDA for marketing the drug in the United 
States by submitting a New Drug Application (“NDA”).53 The 
NDA must include all evidence gathered from the three phases of 
clinical testing, including all animal and human data, the procedure 
by which the drug is manufactured, and information about how the 
drug behaves in humans.54 The FDA can refuse to “file” an NDA 
for review, but must do so within a sixty-day period, though 
refusing to file occurs infrequently.55 
Once the FDA approves a drug and it is ready for the market, 
the FDA’s scrutiny of the drug continues.56 The FDA can require 
drug sponsors to submit additional data from studies after drug has 
obtained market approval.57 These studies are particularly 
important because some safety concerns can only come to light 
after patients have taken the drugs and have reported adverse 
outcomes. The FDA’s management and handling of post-
marketing studies, however, have been the subject of numerous 
concerns.58 According to the a 2015 report by the Government 
Accountability Office,59 these concerns included that (1) the FDA’s 
                                                
 52 Id. 
 53 The FDA’s Drug Review Process: Ensuring Drugs are Safe and Effective, 
supra note 3. 
 54 Id. 
 55 Id. 
 56 Step 5: FDA Post-Market Safety Monitoring, U.S. FOOD AND DRUG 
ADMIN., https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405579.htm. 
(last visited Mar. 20, 2017). 
 57 Id. 
 58 See H.R. REP. GAO-16-192 (2015), 
http://www.gao.gov/assets/680/674183.pdf. 
 59 The Government Accountability Office is an independent and nonpartisan 
government agency that is primarily tasked with investigating how public funds 
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data on tracked issues was not complete, and (2) post-market study 
data was often outdated and contained inaccuracies.60 While post-
market studies can be extremely helpful, especially when it comes 
to using them to support withdrawing a drug from the market, they 
are ineffective if not properly managed. 
C. Special Approval Pathways: An Overview 
As Part B61 of the paper illustrates, there are a rigorous set of 
procedures that must be followed before a drug can be marketed 
for sale in the United States. While these procedures are in place to 
ensure safety and effectiveness and to weed out drugs that pose 
great risk and little benefit, these procedures can also cause great 
delay in allowing potentially effective drugs to be reviewed and 
marketed.62 This is particularly problematic for the individual 
living with a life-threatening disease, for which there is not any 
other treatment available.63 Recognizing this dilemma, the FDA 
has worked with Congress to create “special approval pathways”64 
that speed up the development and review process for drugs that 
meet certain criteria.65 Since the late 1980s, the number of special 
approval pathways has routinely been increasing.66 
Over the past two decades, five programs have been created to 
speed up drug approvals and reviews for illnesses that are either 
rare or life threatening, and for which no other treatment is 
available or for which the new drug suggests greater therapeutic 
                                                                                                         
are used. U.S. GOV’T ACCOUNTABILITY OFF., 
https://www.gao.gov/about/index.html (last visited Mar. 20, 2017). 
 60 H.R. REP. GAO-16-192, supra note 58, at 23. 
 61 See FDA Review Processes for Drugs, supra Part B. 
 62 Aaron S. Kesselheim et al., Trends in Utilization of FDA Expedited Drug 
Development and Approval Programs, 1987-2014; cohort study, 1 BRIT. MED. J. 
2 (2015), http://www.bmj.com/content/bmj/351/bmj.h4633.full.pdf. 
 63 Id. 
 64 Special approval pathways have typically been applied to drugs that treat 
“serious” diseases, and are more readily used when a drug is the first treatment 
for the serious disease or is advantageous over existing treatments for the 
disease. Id. 
 65 Id. 
 66 Id. 
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advantage over existing therapies.67 The five programs are (1) 
orphan drug,68 (2) fast track,69 (3) priority review,70 (4) accelerated 
approval,71 and (5) breakthrough therapy.72 
The number of drugs approved within one of these special 
approval pathways has been increasing over the past two decades, 
perhaps beyond what the FDA intended.73 According to studies, in 
2013, 56% of twenty-seven new drugs were approved under a 
special pathway approval program, and twelve of these drugs 
qualified for more than one program.74 The same study revealed 
that despite the increase in approvals under these programs, many 
of the drugs did not meet the qualifying criteria as being 
“innovative.”75 In fact, many suggest that approvals under special 
pathways have become the rule and not the exception.76 The 
dilemma posed by the Cures Act is whether additional methods for 
expediting drug development and delivery are needed, when 
                                                
 67 Id. 
 68 Under the orphan drug program, a drug qualifies only if it is intended to 
treat a disease that occurs in less than 200,000 people per year in the United 
States. This designation does not change the statutory standards, however 
orphan drugs have been shown to be approved based on “small, non-
randomized, unblended, single arm trials.” Kesselheim et al., supra note 62 at 2. 
 69 A drug qualifies for fast track designation if it treats a “life threatening” or 
“severely debilitating” disease. This designation allows qualifying drugs to be 
approved after just one Phase 2 study. Id. 
 70 A qualifying drug under priority review designation is one that “seems to 
offer therapeutic advance over available therapy.” This does not change the 
statutory standard for approval. Id. 
 71 Under accelerated approval designation, a qualifying drug is one that treats 
“serious or life threatening illnesses,” allowing surrogate endpoints that are 
“reasonable likely to predict patient benefit” to be used. Id. 
 72 A drug is eligible for breakthrough designation if it is one that “treats a 
serious disease for which preliminary clinical evidence suggests substantial 
improvement over existing therapies on one or more clinically important 
endpoints.” This does not change the statutory standard for approval. Id. 
 73 Id. 
 74 Kesselheim et al., supra note 62 at 2. 
 75 Id. 
 76 Margot Sanger-Katz, Speedy Drug Approvals Have Become the Rule, Not 
the Exception, N.Y. TIMES (May 1, 2015), 
https://www.nytimes.com/2015/05/02/upshot/speedy-drug-approvals-have-
become-the-rule-not-the-exception.html. 
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approval pathways already exist, and evidence shows they are 
utilized very frequently. 
D. A Trends Towards Increased Expedited Drug Development and 
Approval Programs 
While special approval pathways have resulted in revolutionary 
drugs, they have also caused great controversy.77 Their increase has 
brought about more drug applications and approvals, but for the 
most part, most of the drugs approved under these expedited 
development programs have not shown “noticeable clinical 
advances.”78 This debunks the belief that the FDA’s clinical-data 
driven process hinders innovation. The FDA’s history is laced with 
tragedies that have brought great scrutiny to the agency’s actions.79 
These tragedies have motivated the FDA to implement regulatory 
reforms.80 In particular, many argue that the pharmaceutical 
industry’s “capture” of the FDA and an increase in special 
approval pathways are what have led to some of the country’s 
worst drug disasters at the hands of the FDA.81 
There are many problems associated with special regulatory 
designations that allow for drug approvals based on less rigorous 
data.82. Notably, there are two problems: (1) basing approvals on 
less rigorous data, and (2) inadequate post-approval procedures for 
these drugs.83 For instance, the case study of gemtuzumab, known 
by its brand name “Mylotarg,” illustrates the dangers of using 
surrogate endpoints84 under accelerated approval pathways.85 
Mylotarg was approved in 2000 for acute myeloid leukemia based 
                                                
 77 Kesselheim et al., supra note 62, at 2. 
 78 Id. at 1. 
 79 Sue McGrath, Only a Matter of Time: Lessons Unlearned at the Food and 
Drug Administration Keep Americans at Risk, 60 FOOD DRUG L.J. 603 (2005). 
 80 Id. 
 81 Id. 
 82 Kesselheim et al., supra note 62, at 2–6. 
 83 Id. 
 84 ”Surrogate endpoints consist of markers such as laboratory measurements 
or radiographic images, and contrast with clinical endpoints such as reduction in 
patient symptoms or mortality.” Id. at 2. 
 85 Id. at 2. 
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on surrogate endpoints,86 however a decade later, it was removed 
from the market after confirmatory post-approval studies found it 
showed “no efficacy and increased mortality.”87 However, the issue 
is that the FDA often delays or fails to complete post-marketing 
studies.88 Much of the information about a drug’s effectiveness is 
learned after the drug has been approved through post-approval 
studies.89 
Expedited approval processes are often created with the belief 
that they will allow new and innovative drugs to reach the 
market.90 While special approval pathways have led to more 
approvals, they have also been used for drugs that present no 
special advantage, thereby presenting greater risk and little benefit 
to patients.91 Given the startling number of drugs approved each 
year based on limited data, the Cures Act drug provisions will 
exacerbate this problem. 
III: LEGISLATIVE HISTORY OF THE CURES ACT: A SUSPECTED 
HOST OF SPONSORS, SUPPORT FOR THE ACT, AND OPPOSITION 
TO THE ACT 
This section will introduce the reader to a very brief legislative 
history behind the Cures Act to include its supporters and its 
critics. This legislative history of the Cures Act is included in order 
to give the reader insight into the circumstances that catapulted the 
passage of the law. 
The strongest proponents of the Cures Act drug provisions 
were pharmaceutical industry stakeholders.92 Almost 1,300 
                                                
 86 Id. 
 87 Id. (“Approving drugs on the basis of surrogate endpoints, for example, can 
be risky, since promising surrogates may later be found not to accurately predict 
actual changes in patient health outcomes.”). 
 88 Kesselheim et al., supra note 62, at 5. 
 89 Id. 
 90 Id. at 1–2. 
 91 Id. at 6. 
 92 Dennis Thompson, Congress Passes 21st Century Cures Act with Billions 
for New Research, Treatment, CBS NEWS (Dec. 8, 2016, 12:34 PM), 
http://www.cbsnews.com/news/21st-century-cures-act-congress-health-care-
passed/. 
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lobbyists from pharmaceutical companies were largely responsible 
for the passage of the entire bill, not shocking, given the financial 
incentive the bill provides for pharma companies.93 Proponents of 
the Cures Act routinely presented the Cures Act in a 
compassionate light, arguing that patients with life-threatening 
illnesses could wait no longer. 
Critics of the Cures Act, however, painted a very different 
picture of the Act. Critics were vocal in their opposition and even 
sent Congressional members a letter to urge them to reconsider 
hastily passing the bill.94 They argued that (1) the bill, as written, 
threatened the ability of the FDA do its job by ensuring safety and 
quality, and (2) that the provisions were unnecessary, given that 
the FDA already used expedited pathways, and even their use was 
raising “serious concerns”95 In the end, however, the 
pharmaceutical industry came out with a victory. Given the Cures 
Act’s support and funding for other noteworthy causes,96 one can 
see how the FDA provisions managed to sneak their way in. Other 
critics of the Cures Act, including Diana Zuckerman, the president 
of the National Center for Health Research, a non-partisan think 
tank, took a stab at the bill, citing the irony of its name.97 
Zuckerman was quoted as saying, “The irony is calling this 21st 
Century Cures, when they’re talking about standards that were left 
behind in the 20th century, because they were found to not be 
good.”98 
One reason often cited for making the FDA’s drug approval 
process less rigorous is that in its current state, it stifles the 
discovery of new drugs and innovation. Critics of this reason, 
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however, offer different explanations. Jerry Avorn, a professor at 
Harvard Medical School presented his theory on the lagging 
innovation in drug development.99 Avorn was quoted as saying, 
If there’s a shortfall in drug development, it is mostly 
because the companies have lost their verve in their ability 
to discover new drugs . . . Lowering FDA standards for 
approving drugs and antibiotics without evidence of 
clinical benefit -- I don’t think that’s going to help, but it 
could also harm patients. What we don’t need is more 
drugs approved based on lab tests instead of patient 
benefit.100 
The Cures Act presents a stark contrast in viewpoints, with 
patients and pharmaceutical industry stakeholders on one side, and 
on the other, physicians. 
IV: THE FUTURE OF DRUG REGULATION: AN ANALYSIS OF HOW 
THE CURES ACT’S EVIDENTIARY STANDARDS FOR DRUG 
APPROVALS WILL UNDERMINE SAFETY AND INNOVATION 
This section provides an in-depth discussion and analysis of the 
key provisions of the Cures Act relating to evidentiary standards 
for drug approvals and the impact of these provisions on safety and 
innovation. Part A discusses the use of real-world evidence to 
support the FDA’s decisions. Part B discusses the use of patient 
experience data in the review process. Part C discusses the Act’s 
mandate on drug development tools in drug development and 
review. Part D discusses the overall implications these three 
provisions will have on drug regulation. 
A.  “Real-World” Evidence: Waning Significance of the Clinical 
Trial 
As discussed in Part II,101 when determining whether a certain 
drug will be approved during the NDA period, the FDA makes its 
determination based on data from clinical trials. Under the Cures 
Act, for drugs that have already been approved by the FDA but are 
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now being considered for a new indication, the agency can utilize 
real world-data in its assessment.102 This provision, however, 
though it provides flexibility in gathering data for review, may 
prove to be ultimately harmful in the end. In its attempt to 
incorporate real-world evidence into the FDA’s regulatory 
approval process, the Cures Act represents perhaps one of the most 
significant moves in clinical trial flexibility in the agency’s history. 
Real-world evidence can come in a variety of forms, and its use 
in the drug approval process can pose noteworthy concerns. Real-
world evidence, according to the Cures Act, is “evidence from 
clinical experience, mean[ing] data regarding the usage, or the 
potential benefits or risks, of a drug derived from sources other 
than randomized clinical trials, including from observational 
studies, registries, and therapeutic use.”103 While the Cures Act 
does not purport to do away with the clinical trial requirement, it 
does bring into question the future of randomized clinical trials, 
given that real-world evidence can now be used as a tool for 
review by the FDA, and can quicken the approval process.104 
For some patients, incorporation of real-world evidence into 
the FDA’s review process seems like a victory.105 As Freeman-
Daily106 points out, clinical trials are not always convenient or even 
possible to conduct due to the low volume of people living with a 
particular rare disease.107 According to Freeman-Dailey’s account, 
They’re [referring to the Cures Act] talking about 
accelerating approval of drugs for patients with rare 
diseases and oncogene-driven cancers like mine. Many of 
these are conditions are infrequent; it would be extremely 
difficult if not impossible to collect sufficient numbers of 
patients for separate clinical trials of each drug in each 
condition. The nearest trial for me is one thousand miles 
away, in Denver . . . Many patients can’t travel. That’s why 
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greater flexibility in trial design for evaluating precision 
medicine drugs is needed . . . 108 
The use of “real-world evidence” in the drug approval process, 
though wrought with controversy in many ways, however, could 
be useful in a number of areas, including its use in tracking 
observational data, a major issue that often arises in the area of off-
label drug use.109 Under the current framework, physicians who 
prescribe off-label are not required to record the purpose for which 
a particular drug is prescribed.110 Under the Cures Act, however, 
medical professionals may be incentivized to share data from 
observational studies for drug-promotion if the data can help in the 
approval process for a drug. Tracking observational data is 
particularly important because it can provide additional 
information to researchers, including what purposes doctors are 
prescribing the off-label drug for, and who they are prescribing it 
to.111 This information could then could used by researchers to 
evaluate whether the drug is safe and effective for the prescribed 
uses, which would save researchers both time and expenses in 
beginning with clinical trials.112 Alternatively, tracking 
observational data also serves a policing function for improper off-
label drug promotion. Particularly, the ability to track 
observational data becomes useful in situations where doctors are 
prescribing off-label drugs when the drug presents little benefit, yet 
high risk, or if there are actual safe and effective existing 
therapies.113 However, tracking observational data may 
alternatively be achieved by incorporating diagnostic codes that 
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include the particular purposes for which a drug is being used into 
Medicare claims. 
Despite the potential incentive to track data from observational 
studies, many argue that the incorporation of real-world evidence 
into approval processes will do more harm than good.114 According 
to scholars, assessing efficacy based on observational data is 
“subject to numerous forms of bias and unmeasured confounding, 
which would obscure the true benefits and risks of drugs and 
devices.”115 Real-world evidence can largely be problematic 
because it is not collected with the intent to support research, and 
thus is not “optimized” for research support.116 Another issue posed 
by using real-world evidence is privacy issues.117 Sharing 
electronic health information from patients who have not 
consented can present significant issues for both the disclosing 
entities and those receiving the data. 118 
Assessing the benefits of incorporating real-world evidence 
into the drug approval process, however, requires further 
addressing the limitations of clinical trials. Among a number of 
concerns that have been identified include, patient recruitment and 
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retention, informed consent issues, gaining Institutional Review 
Board approval, a “shrinking” clinical research workforce, and the 
costs of clinical trials.119 
Real-world evidence, indeed, from patients like Freeman-Daily 
and others, may seem to be valuable in that data would be more 
easily generated than it could be from a clinical trial. This 
provision of the Cures Act could also save researchers a lot of time 
and money when it comes to gathering data. On the other hand, 
however, ease in generating data using real-world evidence will 
come at an expense, and that expense is ensuring that the drug’s 
safety and effectiveness is supported by reliable data. Ancillary 
concerns include the privacy ramifications of using data from 
patients who have not consented to sharing of that data. Further, it 
will delay the development of drugs that have gone through the 
rigorous clinical data-driven review process that presents a greater 
guarantee of effectiveness. 
B. Incorporating Patient Experience into the Review Process 
The Cures Act also aims to incorporate “patient experience” 
into the review process for drugs.120 For the purposes of the 
provision, “patient experience data” is defined as including data 
that, 
(1) are collected by any persons (including patients, 
family members and caregivers of patients, patient 
advocacy organizations, disease research foundations, 
researchers, and drug manufacturers); and 
(2) are intended to provide information about patients’ 
experiences with a disease or condition, including— 
(A) the impact of such disease or condition, or a related 
therapy, on patients’ lives; and 
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(B) patient preferences with respect to treatment of such 
disease or condition.121 
Upon examination of the definition provided in the Cures Act, 
“patient experience” data seems to be very broad. 
Patient experience data can be useful, but as a supplement to 
clinical trials. Patient-reported outcomes (“PROs”) can play an 
important function in the drug approval process.122 FDA 
statisticians have described some of the advantages, including the 
ability of PROs to capture “how a patient feels and functions 
directly from the patient.”123 Another benefit derived from patient 
experience data includes the ability for the patient to be more 
involved in their care.124 Dr. Janet Woodcock, the director of the 
U.S. FDA Center for Drug Evaluation and Research was cited as 
saying that the Cures Act would allow researchers to “collect data 
from a broad range of patients in a ‘structured way,’ 
including details about the burden of their disease and what matters 
to them. This reflects the ‘societal shift from the doctors telling 
you what you have . . . to the patient as a navigator.’”125 Indeed, 
patient experience data could allow for approving drugs based on 
data from more broad patient bases, which is not always possible 
in a clinical trial setting. 
On the other hand, patient experience data also has severe 
downsides. One critique of patient experience data is that including 
personal experience data collected by family members, caregivers, 
and the patients themselves can improperly bias the FDA’s 
otherwise objective review process. 
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C. Qualification of Drug Development Tools 
Under the Cures Act, another provision that has raised 
concerns is Section 3011, which mandates the Department of 
Health and Human Services (“DHHS”) Secretary to certify “drug 
development tools.”126 This section of the paper will briefly 
mention the other drug development tools mentioned in the Cures 
Act under Section 3011, but it will focus on biomarkers, 
specifically surrogate endpoints. According to the provision, a 
“drug development tool” is defined as a “(A) biomarker, (B) a 
clinical outcome assessment, (C) and any other method any other 
method, material, or measure that the Secretary determines aids 
drug development and regulatory review for purposes of this 
section.”127 The Act previously defined a “biomarker,” as “a 
characteristic (such as a physiologic, pathologic, or anatomic 
characteristic or measurement) that is objectively measured and 
evaluated as an indicator of normal biologic processes, pathologic 
processes, or biological responses to a therapeutic intervention; 
and includes a surrogate endpoint.”128 
First, it is important to recognize that using surrogate endpoints 
does, in fact, offer significant benefits, and Section 3011 of the 
Cures Act can help realize these benefits. One of the reasons 
biomarkers are used is because they are cheaper and easier to use 
than clinical endpoints.129 The measurements from biomarkers can 
also be measured more quickly.130 Another advantage with using 
surrogate endpoints is that they can avoid many of the ethical 
issues posed by measuring clinical endpoints.131 
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Surrogate endpoints, however, have been found to be very 
problematic.132 Surrogate endpoints, despite their benefits, are like 
the Cures Act itself: sacrificing safety and reliability for speed.133 
The FDA has even acknowledged the problem with using 
surrogate endpoints, citing that the use of surrogate endpoints 
alone fail to capture the total “picture of benefit and risk of a 
therapy.”134 Some of the limitations of using surrogate endpoints, 
according to the FDA, include: 
For example, surrogate endpoints may sometimes fail to 
predict the overall benefit and/or risk for a medical product. 
These limitations underscore the importance of continued 
evaluation in the post-market phase when products are 
approved based upon surrogate endpoints that have not 
been validated, as well as the need to rigorously evaluate 
and sometimes re-evaluate surrogate endpoints clinically.135 
Under the Cures Act, however, a much greater use of surrogate 
endpoints is encouraged.136 Researchers also point to the harms 
associated with relying too much on surrogate endpoints, including 
medical and financial harm, citing that surrogate endpoints are not 
useful in studying all disease, rather only in cases where the 
“pathophysiology of the disease and the mechanism of action of 
the intervention are thoroughly understood.” 137 
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D. Summary Level Review 
Section 3031 of the Cures Act also allows for data summaries 
to be used in the drug approval process.138 According to Section 
3031: 
(A) The Secretary may rely upon qualified data 
summaries to support the approval of a supplemental 
application, with respect to a qualified indication for a 
drug, submitted under subsection (b), if such supplemental 
application complies with subparagraph (B). 
(B) A supplemental application is eligible for review as 
described in subparagraph (A) only if-- 
(i) there is existing data available and acceptable to the 
Secretary demonstrating the safety of the drug; and 
(ii) all data used to develop the qualified data 
summaries are submitted to the Secretary as part of the 
supplemental application.139 
Data summaries are defined as a “summary of clinical data that 
demonstrates the safety and effectiveness of a drug with respect to 
a qualified indication.”140 In randomized clinical trials, “meta-
analysis of individual patient data is regarded as the gold standard 
in systematic reviews.”141 However, researchers are incentivized to 
deviate from analysis of individual data for three key reasons, 
including the cost, time, and difficulty associated with obtaining 
individual-level data.142 
According to critics, however, data summaries present great 
potential for manipulation by manufacturers. According to Aaron 
Kesselheim, Associate Professor of Medicine at Harvard 
University, 
At present, the FDA usually examines all data put forward 
to support drug approval, including supplemental 
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indications. This herculean effort has proven necessary 
because manufacturers have sometimes been found (often 
through litigation) to summarize their data in ways that 
excessively emphasize benefits of their products and 
minimize risks.143 
Greater use of data summary in the approval process, per the 
Cures Act, poses a threat to patient safety. 
E. A Step Back in Time? 
Each of the three sections of the Cures Act provide for 
significant changes in the drug approval process. While each 
individually poses benefits, these benefits do not outweigh the 
risks associated with relying on less rigorous data for drug 
approval. Benefits, such as cost-saving and efficiency are 
noteworthy. However, where public health disasters are at stake, 
these benefits cannot supersede the FDA’s duty to protect public 
health by approving only those drugs that have been adequately 
and rigorously tested and are based on rigorous data. 
As the drug and device provisions indicate, quick delivery as a 
goal seems to be gaining traction among the FDA’s review 
processes. While the randomized clinical trial is here to stay, it 
remains questionable how much significance the FDA wields 
given that new forms of review tools, like real-world evidence and 
a greater reliance on surrogate endpoints and patient experience, 
with less stringent standards are now available for the FDA’s use. 
These provisions of the Cures Act, indeed, may represent a step 
backwards for the FDA. Given the agency’s past history, this may 
present itself to be a dangerous step. 
V: BROADER IMPLICATIONS AND NECESSARY REFORMS FOR A 
LESS THAN IDEAL SYSTEM OF DRUG APPROVALS AND RECALLS 
The Cures Act will redefine the game when it comes to getting 
drugs on the market. However, the Cures Act is also wrought with 
real implications, many of which will be harmful to the future of 
safe and effective drugs. There are concerns about how patients 
                                                
 143 Aaron S. Kesselheim & Jerry Avorn, New “21st Century Cures” 
Legislation: Speed and Ease vs. Science, 317 JAMA 581, 582 (2017). 
APRIL 2016] 21st Century Cures Act 433 
will fare under the Cures Act, with the potential that they will now 
be exposed to treatments and devices that have not been adequately 
tested and whose risks and safety concerns are not completely 
known. There are concerns that the intrusion of less rigorous data, 
such as patient experience data into the review process will erode 
trust in the FDA’s approval process. 
One of the biggest issues with the Cures Act’s provisions on 
evidentiary standards for drug approvals, however, can be viewed 
through the lens of the current framework for drug recalls and 
through an analysis of the FDA’s effectiveness and diligence in 
adequately monitoring post-market approval studies. The stand-
alone drug provisions in the Cures Act by themselves are 
controversial, but coupled with a slow and lengthy drug recall 
process, and inadequate post-market approval studies by the FDA, 
the problem is magnified. Provisions like the ones in the Cures Act 
that speed up drug approvals demand urgent mechanisms for 
addressing the ramifications that can result from approvals based 
on less reliable data. Currently, the FDA’s mechanisms for 
addressing drugs that pose risks after approval are inadequate.144 If 
a drug that has been approved based on using the methods in the 
Cures Act presents danger, the “back-end” procedures must be in 
alignment with the “front-end” procedures, ensuring that the drug 
can be removed quickly, or that the manufacture can remedy the 
problem before it causes more harm.145 
For low-income patients, the Cures Act will even pose more of 
a risk.146 Physicians, who are given samples by drug companies, 
often give low-income patients these samples for free.147 While this 
seems at first glance a controversial practice, it is also a means by 
which low-income patients can access drugs that may help them 
that would otherwise be unavailable to them.148 However, the main 
dilemma is that the free samples tend to be drugs that have been 
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newly approved.149 According to Dr. Reshman Ramachandran, an 
assistant scientist at the Johns Hopkins Bloomberg Institute of 
Public Health, 
The concern [I have], especially for underserved 
populations, is that the things we have in our back pocket—
through sample closets or discount cards—would be 
approved based on a lower standard,” she said. “It’s a bad 
mix—giving our underserved populations access to 
potentially unsafe and ineffective drugs.150 
Approvals under the Cures Act will put an already 
disadvantaged population in harm’s way, posing both safety and 
ethical implications. 
Beyond safety and efficacy concerns, the bill also raises other 
dilemmas, including financial waste. If treatments are not adequate 
and rigorously tested and lack strong scientific support, insurers 
may potentially dole out resources for treatments that may prove 
later to be medically ineffective.151 Relatedly, many proponents of 
relaxed regulatory burdens on drugs entering the market argue that 
doing so will actually bring down the alarmingly high costs of 
prescription drugs.152 Their argument follows that introducing 
multiple drugs into the market that treat the same condition will 
create competition and decrease prices.153 However, this has not 
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been the case.154 On a similar note, expedited drug approval and 
development also will result in financial waste of government 
resources.155 
The Cures Act may also present opportunity for product 
liability suits when persons are harmed by taking a drug that has 
been approved based on less rigorous data. This problem is 
particularly amplified in light of the public’s general 
misconception regarding FDA approval to begin with.156 Many 
patients do not fully understand what the FDA’s “seal of approval” 
means.157 According to a study by researchers regarding the 
meaning of FDA approval, patients had several misconceptions 
about FDA approval, including, (1) that the FDA approves only 
those drugs that are extremely effective, (2) that the FDA does not 
approve drugs with serious side effects, and (3) that the FDA only 
allows those drugs that are ‘extremely effective’ to be 
advertised.”158 The general problem seems to be that FDA approval 
is demonstrative of efficacy level certification.159 The public’s trust 
in “FDA approval” may be sorely misplaced when FDA approval 
processes under the Cures Act accept less rigorous data, a fact 
which consumers may be unaware of. 
Finally, another concern surrounds the question of what the 
Cures Act means for the direction of regulation moving forward 
and the legitimacy of the FDA. In an era in which the current 
administration has already taken a strong approach towards 
deregulation,160 the safety and effectiveness of drugs remains an 
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issue. The Trump Administration’s executive order, promulgating 
that for every new government regulation, the government must 
get rid of two existing regulations, also presents significant 
uncertainty about the implementation of the Cures Act, particularly 
as to how much its implementation will be delayed.161 The Cures 
Act’s representation of a continued trend towards lax regulation 
may very well undermine the objective of the FDA: to promote 
and protect public health. 
On the other hand, the FDA’s management of the clinical trial 
process has also been imperfect and demands the agency’s 
attention.162 In a 2015 study, researchers found that the FDA was 
not transparent in communicating findings to the scientific 
community about deviations from “good clinical practice and 
research misconduct” the FDA discovered from inspecting clinical 
sites doing research on human participants, resulting in reliance on 
data from faulty clinical trials.163 
VI: CONCLUSION 
While the FDA drug approval process could benefit from 
reforms that might bring therapies to the market quicker, the 
provisions in the Cures Act may run counter to their very intent: to 
give patients access to effective drugs and therapies and to 
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encourage innovation. Drugs that have not undergone the rigors of 
the usual FDA process characterized by the controlled clinical trial 
present significant safety risks to the patients the agency is tasked 
with protecting. Further, allowing drugs to be approved based on 
less rigorous standards delays the development of other drugs that 
have undergone the rigors of a controlled clinical trial and are 
more likely to pose less safety and efficacy issues for patients. 
Real-world evidence, drug development tools like biomarkers, 
and patient experience data have presented benefits that the clinical 
trial itself cannot achieve, including flexibility, ease in generating 
data, and cost-cutting results. However, none of these can serve as 
substitutes for controlled clinical trials, even with their 
imperfections. 
Until the current system of drug recalls is improved and post-
marketing approval studies are better monitored and conducted, 
further loosening of drug approvals standards will not solve the 
problem of stifled drug development and innovation. If the trend to 
reduce burdens upon drug sponsors when initially approving a 
drug continues, then removal procedures must be proportional in 
order to ensure that potentially unsafe and ineffective drugs can be 
removed from the market. Additionally, reducing evidentiary 
burdens for drug approvals presents a host of other issues, not 
limited to privacy, ethical, financial, and reimbursement-related 
concerns. 
The FDA must balance two competing interests: (1) ensuring 
that patients—especially those who are in dire situations—can 
access effective drugs and treatments, where other therapies or 
alternatives might not exist, and (2) at the same time, ensuring that 
the safety and effectiveness of drugs are not being compromised 
simply for speed. In the end, the FDA is presented with the quality 
versus quantity and access dilemma and must remember to stay 
true to its objectives. 
